The Effect of COVID‐19 on Platelet Counts in Persistent and Chronic Adult ITP Patients: A Real‐World Study in China
ABSTRACT Objective While coronavirus disease 2019 (COVID‐19)‐associated thrombocytopenia is well‐documented, its effects on immune thrombocytopenia (ITP) patients remain unclear. This study aimed to investigate the impact of COVID‐19 infection on platelet (PLT) dynamics in chronic ITP patients. Meth...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.70025 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | ABSTRACT Objective While coronavirus disease 2019 (COVID‐19)‐associated thrombocytopenia is well‐documented, its effects on immune thrombocytopenia (ITP) patients remain unclear. This study aimed to investigate the impact of COVID‐19 infection on platelet (PLT) dynamics in chronic ITP patients. Methods This retrospective study analyzed 21 persistent and chronic ITP patients before and after mild COVID‐19 infection during China's December 2022 reopening, comparing platelet parameter changes with a focus on clinical characteristics of thrombopoietin receptor agonist (TPO‐RA) treated patients. Results TPO‐RA treated patients demonstrated transient platelet surges peaking at 1 week postinfection, returning to baseline within 2–3 weeks, contrasting sharply with thrombocytopenia patterns in non‐ITP populations. This suggests synergistic effects between virus‐induced inflammatory cytokines and TPO‐RA may drive transient megakaryopoiesis. Conclusion These findings underscore infection‐related PLT fluctuations in ITP, necessitating monitoring for thrombotic and bleeding risks and TPO‐RA dose optimization during infections. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission |
|---|---|
| ISSN: | 2688-6146 |